Shineco

What Shineco does

Shineco, Inc. is a Delaware-incorporated holding company founded in August 1997 and headquartered in Beijing, China, that operates a diversified portfolio of medical, biotech, and consumer health businesses through majority-owned subsidiaries in China, Hong Kong, Singapore, and the United States. The company's stated core technology platforms are induced pluripotent stem cell (iPSC) technology and extracellular vesicle-derived products, supported by Changzhou Biowin Pharmaceutical's 33 Chinese medical device registration certificates, EU CE certification, and registrations in Australia, Spain, Thailand, and Japan across 15 product series and 45 SKUs. Flagship clinical products include the Cardiac 5-Minute Test, the only NMPA-approved cardiac marker test in China completing troponin I / myoglobin / heart fatty acid binding protein detection in under five minutes, and a portfolio of COVID-19 antigen, nucleic acid, and IgG/IgM antibody kits. Through its 51% acquisition of Singapore-based InfiniClone Limited (April 2025) the company holds 29 global patents covering cell reprogramming, microcarrier-based stem cell culture, and iPSC library establishment, claimed to deliver 3-10x cell expansion throughput and >60% per-cell cost reduction.

The business model is a mix of medical device hardware sales, distribution licensing, and consumer products. Revenue streams include POCT diagnostic sales through Chinese hospital channels and Amazon Germany (Changzhou Biowin), water-soluble phospholipid concentrate beverages distributed via six partners with $30M+ projected three-year sales, durable medical equipment sharing through the LOI-stage Meitong Technology target (800+ hospitals, RMB ~600M cash flow), Class II/III medical device manufacturing via the 75%-owned FuWang (HK) International (projected $11M revenue in 2025), antibacterial silk fabric manufacturing through Chongqing Wintus (71.42%-owned via Dream Partner Limited), and a single 'Meida Nutritionary Restaurant' carry-out location in Fuzhou. Go-to-market combines enterprise hospital sales, distributor/reseller networks, marketplace e-commerce, and physical retail. Customer segments span Chinese hospitals and cardiology departments, Southeast Asian consumers via Total World Marketing, German Amazon shoppers, and elderly care targets through the Turing Video strategic cooperation.

Financially, Shineco completed its NASDAQ IPO in 2016 under ticker TYHT (changed to SISI in October 2021) and was delisted from NASDAQ in November 2025 after a multi-month trading suspension. Capital raises are modest ($2.0M in 2021 from GHS Investments, $2.2M in 2022, ~$7M private placement in June 2024), while acquisitions have been funded through a combination of cash and stock (~$19.9M plus 3.45M shares for InfiniClone, ~$8.8M plus 3.4M shares for FuWang). No consolidated revenue or ARR figure is disclosed in available sources. The company is operationally active, with a new Biological Cell Digital Business Division established in August 2025 to integrate iPSC cell assets with blockchain infrastructure.

Name

Shineco

Legal name

Shineco, Inc.

Website

https://biosisi.com

Company type

Public

Founded year

1997

Operating status

Operating

Headcount range

101–250 employees

Short description

Shineco is a Delaware-incorporated, formerly NASDAQ-listed holding company (delisted November 2025) that develops and distributes POCT diagnostics, iPSC-based regenerative medicine products, phospholipid health food beverages, antibacterial silk fabrics, and Class II/III medical devices, primarily serving Chinese hospitals, Southeast Asian consumers, and European online buyers.

Ownership category

akta.pro rank

Product category

In-vitro diagnostics and medical devices

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Medical and Diagnostic Laboratories (62151), Pharmaceutical Preparation Manufacturing (325412)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841), Services-Medical Laboratories (8071), Pharmaceutical Preparations (2834)

akta.pro primary industry

Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL)

Keywords

• Point-of-care diagnostics
• In-vitro diagnostic reagents
• Regenerative medicine
• Induced pluripotent stem cell
• Medical device manufacturing

Headquarters

HQ city

Jinling

HQ country

China

HQ region

Asia

Offices7 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Medical Devices and Diagnostics Sales: Sale of POCT products including cardiac tests, COVID-19 tests, and diagnostic reagents. Changzhou Biowin Pharmaceutical sells products domestically and internationally, including through Amazon's German platform. FuWang Company specializes in Class II and III medical devices including biochemical analyzers, patient monitors, and mobile medical imaging workstations.
2. Health Food and Beverage Products: Distribution agreements for water-soluble phospholipid concentrate health food beverage with projected sales exceeding $30 million over three years. Healthy carry-out restaurant operations under 'Meida Nutritionary Restaurant' brand.
3. Medical Equipment Manufacturing and Sales: Joint venture Shangkang Life Science produces and sells medical equipment and personal protective equipment. Kangling Medical contributes bone hyperplasia rheumatism treatment instruments with multiple Class 2 medical device licenses.
4. Durable Medical Equipment Rental and Shared Products: Meitong Technology provides shared medical products to hospitals, healthcare facilities, and home patients including wheelchairs, hospital beds, and power banks with annual cash flow of nearly RMB 600 million.
5. Antibacterial and Antiviral Silk Fabric Products: Sale of antibacterial and antiviral fabrics using mulberry silk raw material manufactured by Chongqing Wintus Group, with production bases in India, mainland China, and Hong Kong.
6. Stem Cell and Regenerative Medicine Products: InfiniClone produces molecular detection kits based on iPSC technology and Purelix series health products for immune enhancement, brain nerve support, and antioxidant solutions. Distribution through Total World Marketing in Southeast Asian supermarket, pharmacy, clinic, and e-commerce channels.
7. Medical Device R&D and Manufacturing: FuWang Company generates projected revenues of US$11.03 million (2025), US$13.79 million (2026), and US$17.24 million (2027) from R&D, production and commercialization of Class II and III medical devices.
8. Private Placement Financing: Company raised approximately $7 million through private placement of 1,400,000 shares at $5.00 per share for working capital and strategic initiatives.

Pricing tiers

Go-to-market motion3 records

Distribution channels6 records

Marketing channels7 records

Core offering

Shineco researches, develops, manufactures, and distributes point-of-care testing (POCT) diagnostic kits and medical devices, iPSC-based regenerative medicine products, antibacterial/antiviral silk fabrics, and health food beverages. Its core platform comprises 33 in-vitro diagnostic reagents and related medical devices produced mainly through the Changzhou Biowin subsidiary, the InfiniClone iPSC technology platform with 29 global patents, and a portfolio of Class II/III medical devices (biochemical analyzers, patient monitors, mobile imaging workstations). Distribution reaches 800+ hospitals in China, global markets via Amazon, and consumer channels through the Meida Nutritionary Restaurant brand.

Product overview

Shineco operates as a diversified healthcare company with a multi-product portfolio centered on medical diagnostics, regenerative medicine, and health products. The core business encompasses induced pluripotent stem cell (iPSC) technology platforms and extracellular vesicle-derived products, supported by 33 vitro diagnostic reagents and related medical devices. The product portfolio includes POCT (Point-of-Care Testing) products spanning 15 series and 45 product varieties, highlighted by the Cardiac 5-Minute Test which was the first NMPA-approved cardiac marker test in China completing detection in 5 minutes. COVID-19 diagnostic products include antigen, nucleic acid, and antibody test kits. The company has expanded into regenerative medicine through acquisition of InfiniClone with its iPSC technology platform and molecular detection kits, as well as Purelix health products. Additional offerings include health food products (water-soluble phospholipid concentrate beverage, Meida Nutritionary Restaurant), antibacterial silk fabrics, and various medical devices (biochemical analyzers, patient monitors, electro-acupuncture devices). A new Biological Cell Digital Division integrates blockchain technology with iPSC assets for standardized cell asset management.

Differentiator

Problem solved

Functional benefit

Brands

• Changzhou Biowin Pharmaceutical Co., Ltd. POCT testing subsidiary with 33 Chinese medical device registration certificates, EU CE certificate, producing cardiac tests and other diagnostic products
• InfiniClone
• Meida Nutritionary Restaurant
• Purelix

Products and services

• Cardiac 5-Minute Test Combination diagnostic test detecting cardiac troponin I, myoglobin, and heart fatty-acid binding protein for the clinical diagnosis of acute myocardial infarction (AMI) within 5 minutes. First and only product in China to complete cardiac marker detection within 5 minutes (vs. 15+ minutes for competitors); meets US, European, and Chinese AMI 10-minute guidelines and requires no cold-chain transportation.
• Point-of-Care Testing (POCT) Product Line 15-series/45-product POCT portfolio developed by Changzhou Biowin Pharmaceutical covering cardiac tests, COVID-19 tests, fecal specimen collection devices, and additional disease-detection assays. 5 series and 24 products are sold domestically; 10 series and 21 products are sold internationally, with 33 Chinese medical device registration certificates, EU CE certification, and country-level registrations in Australia, Spain, Thailand, and Japan.
• Novel Coronavirus (COVID-19) Antigen Test Kit (Colloidal Gold) Rapid antigen detection test for COVID-19 using colloidal gold methodology, intended for clinical and over-the-counter point-of-care use.
• Novel Coronavirus (COVID-19) Nucleic Acid Test Kit (Fluorescence RT-PCR) Fluorescence RT-PCR nucleic acid test for COVID-19 designed for laboratory and clinical molecular diagnostic use.
• Novel Coronavirus (COVID-19) IgG/IgM Antibody Test Kit (Colloidal Gold) Colloidal gold IgG and IgM antibody-detection test for COVID-19, used for immune-status assessment and post-infection screening.
• Disposable Stool Test Sample Collector (In-situ Fecal Specimen Sampling Device) In-situ fecal specimen sampling device covered by an exclusive global patent and FDA marketing approval, intended for clinical laboratory examination and diagnostic workflow use.
• Water-Soluble Phospholipid Concentrate Health Food Beverage Health food beverage developed using Shineco's patented pure physical extraction technology with water solvent large column chromatography ultrafiltration membrane that protects the natural structure and activity of phospholipids while restoring their natural bilayer structure. Distributed globally for use as a functional food and beverage ingredient and finished drink product.
• Antibacterial and Antiviral Silk Fabrics Mulberry-silk-based antibacterial and antiviral fabrics manufactured by Chongqing Wintus Group with production bases in India, mainland China, and Hong Kong. End applications include silk antibacterial masks, medical dressings, medical textiles, biodegradable silk bone nails, and silk-based photoresists for lithography.
• Biochemical Analyzers Class II and III medical device biochemical analyzers developed by FuWang (HK) International Company Limited for clinical chemistry analysis in hospital and laboratory environments.
• Patient Monitors Class II and III medical device patient monitors from FuWang (HK) International for tracking vital signs in hospitals, ICUs, and other clinical care settings.
• Mobile Medical Imaging Workstations Class II/III mobile medical imaging workstations from FuWang (HK) International enabling portable diagnostic imaging at the point of care across hospital and remote settings.
• Bone Hyperplasia Rheumatism Treatment Instruments Medical instruments for the treatment of bone hyperplasia rheumatism, manufactured through the Shangkang Life Science joint venture leveraging Kangling Medical's multiple Class 2 medical device licenses.
• Electro-Acupuncture Devices Electro-acupuncture devices under joint development that release specific biomolecules to enhance therapeutic outcomes for rehabilitation and recovery of elderly patients.
• InfiniClone iPSC Technology Platform Induced pluripotent stem cell (iPSC) platform incorporating cell reprogramming technology, microcarrier-based stem cell culture, and iPSC library establishment; covered by 29 global patents and designed for regenerative-medicine applications including Parkinson's, Alzheimer's, and stroke treatment cycles shortened from months to weeks.
• InfiniClone Molecular Detection Kits Molecular detection kits based on iPSC technology that analyze genetic mutations for diseases including diabetes, cancer, Alzheimer's disease as well as drug-response, skin characteristics, and nutritional-metabolism genetic traits. Distributed through Total World Marketing in Southeast Asia.
• Purelix Series Health Products Tailored dietary supplements designed to address immune enhancement, brain-nerve support, and antioxidant solutions based on each customer's InfiniClone molecular detection kit results, providing symptomatic relief in line with personalized health management plans.
• Meida Nutritionary Restaurant Carry-Out Meals Healthy carry-out meals built on life-science research for metabolic health intervention, aimed at regulating insulin resistance and improving glucose and lipid metabolism for chronic metabolic-disorder prevention and management.
• Shared Hospital Medical Equipment (Meitong Technology) Shared hospital and home medical equipment rental including wheelchairs, hospital beds, and power banks, distributed to 800+ Chinese hospitals and home patients and coordinated through an intelligent management system; nearly RMB 600 million annual cash flow.
• Biological Cell Digital Services Blockchain-enabled biological cell asset management services providing standardized iPSC cell bank tracking, blockchain-linked compliance frameworks, and equity-transfer mechanisms for cell-asset circulation, traceability, and ownership transfer.

Quantifiable outcome

• 5-minute cardiac marker detection vs. 15+ minutes for competitors
• +6 more outcomes

Named customers5 records

Segments6 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Total World Marketing (Thailand)coreChannel Partner/ Reseller/ Distributor · 13 May 2025Strategic distribution agreement with Total World Marketing (Thailand) for InfiniClone's molecular detection kits and Purelix series health products in Southeast Asian market. TWM launched pilot sales through Thailand supermarket channels with plans to expand to pharmacies, clinics, and e-commerce platforms after obtaining Thai FDA approval for molecular detection kits.
• Dr. Lim Kah MengcoreStrategic or Co-development Partner · 22 April 2025Share Purchase Agreement signed April 22, 2025, for acquisition of 51% equity interest in InfiniClone Limited for $19,895,600 cash and 3,450,000 shares of Company common stock. Dr. Lim is founder of InfiniClone with over 20 years of molecular research experience in stem cell research, regenerative medicine, and neuro medicine therapies.
• Yi Yang (Seller of FuWang Company)coreStrategic or Co-development Partner · 20 March 2025Stock Purchase Agreement signed March 20, 2025, for acquisition of 75% equity interest in FuWang (HK) International Company Limited for approximately US$8.8 million cash, 3,400,000 shares of Company common stock, and transfer of 71.42% equity interest in Dream Partner Limited. FuWang Company specializes in R&D, manufacturing, and commercialization of Class II and III medical devices.
• Beijing Oriental Meitong Technology Co., Ltd.coreStrategic or Co-development Partner · 18 June 2024Investment Letter of Intent signed June 18, 2024, for Shineco to invest $20 million in Meitong Technology for 80% equity interest. Meitong Technology provides shared medical products to over 800 hospitals across China with nearly RMB 600 million annual cash flow. Acquisition expected to expand Shineco's business in nursing, home medical, funeral equipment, and medical supply rental markets.
• Turing Video (Shenzhen) Co., Ltd.coreStrategic or Co-development Partner · 14 June 2024Strategic Cooperation Framework Agreement signed June 14, 2024, between Shangkang Life Science and Turing Video to jointly develop smart medical products combining biotechnology with AI. Turing Video contributes over 40 patents related to 60GHz vital sign monitors, smart fall monitors, and AI infant care products, serving customers in over 20 countries. Joint development of systems combining miniature biosensors with smart camera equipment for elderly health monitoring.
• Dream Partner LimitedcoreStrategic or Co-development Partner · 19 September 2023Acquisition of 71.42% equity interest closed September 19, 2023. Dream Partner owns 100% of Chongqing Wintus Group, a manufacturer of antibacterial and antiviral fabrics using mulberry silk as raw material with production bases in India, mainland China, and Hong Kong. Chongqing Wintus' production bases and mulberry silk technology innovation centers support healthcare and medical product applications.
• Yangzhou Kangling Medical Co., Ltd.coreStrategic or Co-development Partner · 15 June 2023Joint venture agreement signed June 15, 2023, establishing Shangkang Life Science and Technology (Jiangsu) Co., Ltd. with 51% contribution from Shineco Life Science and 49% from Kangling Medical. Joint venture capitalized at RMB 10.0 million (approximately US$1.4 million) for R&D, production, and sale of medical equipment and personal protective equipment. Kangling Medical brings multiple Chinese national Class 2 medical device licenses and expertise in bone hyperplasia rheumatism treatment instruments.
• All-China Federation of Industry and Commerce Medical & Pharmaceutical Chamber of CommerceminorOthers · 1 May 2023Shineco Life Science Research Co., Ltd. registered as member of the Pharmaceutical Chamber of Commerce in May 2023. The Chamber operates directly under the All-China Federation of Industry and Commerce and consists of approximately 1,500 direct members and more than 50 group members encompassing over 5,000 pharmaceutical companies across all Chinese provinces and municipalities.
• Beijing Wonner Biotech Co., Ltd.minorStrategic or Co-development Partner · 5 October 2021Planned acquisition of over 51% equity interest for up to $30 million to jointly develop SNG, a natural rapid-acting antidepressant medicine. Acquisition aimed at accelerating SNG's clinical development and market application for depression treatment.

Scale indicators13 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• FATE Therapeutics: US clinical-stage biopharma developing iPSC-derived cellular therapies for cancer and autoimmune diseases. Directly comparable to Shineco/InfiniClone's iPSC platform because both bet on induced pluripotent stem cell technology as the manufacturing backbone for off-the-shelf cell therapies.
• Sinocare Inc. Leading Chinese POCT diagnostics company focused on blood glucose monitoring and broader rapid diagnostics. Comparable to Shineco's Biowin unit as a China-based POCT player with hospital and consumer channels and multiple NMPA-approved diagnostics.
• ACON Laboratories: US-headquartered rapid diagnostics manufacturer with strong private-label and OTC POCT presence, including infectious disease tests sold through retail and e-commerce channels. Directly comparable to Shineco's COVID-19 antigen/antibody/nucleic acid kits sold on Amazon Germany.
• Wondfo Biotech: Chinese POCT leader with a broad portfolio of rapid diagnostic tests including cardiac markers, infectious disease, and women's health. Closely comparable product overlap with Shineco's cardiac and infectious disease POCT kits and similar hospital/clinic distribution model in China.
• QuidelOrtho: Major US-based POCT diagnostics company (Triage cardiac markers, Sofia rapid tests). Directly comparable to Shineco's Changzhou Biowin POCT franchise and Cardiac 5-Minute Test as both sell rapid immunoassay diagnostics to hospitals and physicians' offices.

Broad incumbents

• BGI Genomics: Chinese genomics and molecular diagnostics leader offering IVD reagents, sequencing services, and at-home molecular test kits. Comparable to InfiniClone's iPSC-based molecular detection kits and Shineco's broader IVD reagent portfolio given shared focus on molecular diagnostics and clinical channels.
• Yuwell Medical: Chinese medical equipment company covering durable medical equipment, patient monitoring, and home healthcare. Comparable to Shineco's Meitong hospital-equipment-sharing and FuWang patient-monitor portfolio through similar hospital channels and chronic-care positioning.
• Mindray Medical: Largest Chinese medical device company offering patient monitors, in-vitro diagnostics, and medical imaging systems. Comparable to Shineco's FuWang biochemical analyzers, patient monitors, and mobile imaging workstations as a broad-line Chinese medtech with overlapping hospital channel.

Emerging players

• Pluristem Therapeutics: Cell therapy company using placenta-derived stem cells for regenerative indications. Comparable as a regenerative-medicine peer addressing similar neurological and inflammatory disease targets as Shineco's iPSC-based pipeline claims for Parkinson's, Alzheimer's, and stroke.
• Century Therapeutics: Clinical-stage iPSC-derived allogeneic cell therapy developer. Closely parallels InfiniClone's iPSC technology stack and regenerative medicine focus, with similar differentiation arguments around scalability and cost.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries9 records

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Shineco